NeuroSense Therapeutics Ltd.
NRSNDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Dec 1, 2026
11wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PrimeC | Phase 2 | Alzheimer Disease | - | - |
Alzheimer Disease
1 drug in this indication
ALS
1 drug in this indication
Amyotrophic Lateral Sclerosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NeuroSense Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in NeuroSense Therapeutics Ltd.'s (NRSN) pipeline across Phase 2. Its lead program is PrimeC (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NeuroSense Therapeutics Ltd.'s next FDA catalyst?→
NeuroSense Therapeutics Ltd.'s (NRSN) next tracked catalyst is a NDA Filing expected December 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NRSN biotech catalysts?→
Add NRSN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NeuroSense Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.